Establishment Labs Holdings Inc. , a global medical technology company dedicated to improving women's health and wellness in breast aesthetics and reconstruction, announced it has launched Preservétm ...

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health ...

Researchers went on to compared these findings with other previously published studies, noting that that progression-free survival and overall survival benefits from reoperations may vary. “Overall, ...

According to published results, nonoperative treatment yielded similar clinical outcomes at 2 years as operative treatment ...

Tafinlar and Mekinist combination therapy shows efficacy in glioma treatment for both pediatric and adult patients, with higher response rates in pediatric cases. Objective response rates were 53% for ...

According to published results, stem design was the strongest predictor of postoperative periprosthetic femoral fracture ...

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced data from the AMDS PERSEVERE clinical trial (the "IDE") was presented in a ...

Full IDE Data Set Demonstrates Sustained Benefit at One Year with Use of AMDS in Acute DeBakey Type I (ADTI) Dissections Complicated by Malperfusion Data from the trial demonstrate sustained ...